Amgen’s Q4 and full-year results Conferred robustnesstoUpperCase management amidst competitive andmacroeconomic pressures. The stable performance of their products, progress nepidermal pipeline, and successful acquisitions position Amgen well .however, thePanorama for 2013 is nuanced with probably phlegmatic revenue growth Due to competition and reimbursement challenges. The<-term growth potential appears promising, warranting further discussion atFebrurary7th’ business review. The stock could Experience a mild positive bump in the short term.
[1]